Gsk Share Discussion Threads

[philanderer] 16/7/2017 09:25

The influence of overseas drugs giants in the UK healthcare system could come under scrutiny after it emerged that foreign firms are the driving force behind a judicial review challenge to new NHS drug pricing powers.

Sunday Telegraph

[solomon] 15/7/2017 12:39

Decisions, decisions. There is a 21 month long upward trending support line on the chart which stands at around 1560 (and rising, of course) just now. I would be thinking a lot about what to do, if it broke down through that trend line. Cross that bridge whwn we get to it.

[grahamite2] 15/7/2017 11:43

I'm in two minds whether to get back in. Being in the same position as before, except £1 cheaper, can't be bad. On the other hand I sold in the first place against the likelihood of a general pullback in the market.

[ny boy] 15/7/2017 10:54

Down, up, down ..a bit wobbly,stronger £ not helping

[alphorn] 14/7/2017 17:50

EI - LOL's!

[ny boy] 14/7/2017 14:00

On the rise again!

[essentialinvestor] 14/7/2017 11:18

It's largely down to how the strategic update is viewed, anyone's guess.


Alp, very witty!.

[montyhedge] 14/7/2017 10:43

Support at 1600p if broken 1525p on the cards.

[ny boy] 14/7/2017 10:06

Back to test 1600p again, will top up with another £25k if we get to 1560/1575p area

[alphorn] 14/7/2017 08:58

"Witty rates GlaxoSmithKline a ‘buy’"

He would wouldn't he? ;))

[philanderer] 14/7/2017 08:42

All eyes on Walmsley’s Glaxo revamp


Jefferies is staying positive on shares in GlaxoSmithKline (GSK) as chief executive Emma Walmsley continues to stamp her mark on the drugs group.

Walmsley took over from Andrew Witty in April, and Jefferies analyst Jeffrey Holford expects her to cut back on some of the group’s drugs in development.

‘The strategic update is likely the key factor near term, which we think may be punctuated by some pruning of the pipeline and redefinition of the research and development strategy going forward,’ he said.

Witty rates GlaxoSmithKline a ‘buy’ and has a £19 price target on the shares, which were trading at £16.19 yesterday.

‘Underlying business trends are expected to be positive in pharma as the [cough and asthma treatment] Breo launch continues to improve and [HIV products] Tivicay / Triumeq volume growth remains strong,’ he added.

Holford has marginally lowered revenue estimates but edged forecasts for 2017 earnings per share higher after reviewing his model.

[tradermichael] 14/7/2017 08:38

Barclays Stockbrokers .... dividends in accounts this morning ..... ;0)

[m_k_hubbert] 13/7/2017 23:09

HL, dividend in account this morning.

[philanderer] 13/7/2017 17:52

Pfizer’s medicinal sciences head Tony Wood jumps ship to GSK

[tradermichael] 13/7/2017 13:41

Scotches - agree. I'm planning to move from Barclays to AJ Bell.

[philanderer] 13/7/2017 12:40

Selftrade , time stamped at 3:25:56 in the early hours today :-)

[scotches] 13/7/2017 12:18

Barc have always been slow to credit divis. Is there some financial benefit to them of the cash not being credited to client accounts immediately.

After almost 20 years it is time to move on since there is a new fee about to be imposed via their smart investor platform. I left their ISA and SIPP products previously because of needlessly high fees - there are better and cheaper options for a simple trading account elsewhere. Will see how smoothly the transfer is managed - no fees on exit.

[sicker] 13/7/2017 12:11

I'm with tdw (now II) Mine was visible when I checked at 08.45.:-)

[sicker] 13/7/2017 12:11

It's showing but can't be accessed until tomorrow.

[toffeeman] 13/7/2017 11:31

AJ Bell - in account this am

[andyadvfn1] 13/7/2017 11:06

In my Halifax account since 10am

[dr biotech] 13/7/2017 10:57

Not showing in my Halifax account. Typically it shows by the close and is accessible the day after. Its about £200 for me - not enough to reinvest, I just let all my divis add up then find buy some no hoper at the peak..

[ny boy] 13/7/2017 10:53

Bought another £25k's worth this morning.